We have a vision
By 2050, the number of people suffering from Alzheimer’s disease will have tripled, affecting a projected 13.8 million people in the US alone. Early detection of this horrible disease is crucial. We’re focused on a solution.
At Optina Diagnostics we’re focused on the development of technology for the early detection of disease through the eye.
With a first application in the diagnosis of Alzheimer’s disease, our technology detects the likely PET amyloid status (Positive or Negative), a key biomarker of this disease.
The solution to a cure for Alzheimer’s begins with the early detection of the disease in order to treat it before irreversible damage occurs. This is an important step.
The Optina Diagnostics retinal imaging test involves a scan of the retina, using equipment and technique that is similar to the fundus photography, which is already being used by ophthalmologists to diagnose retinal diseases.
The Optina Diagnostics test scans the retina and the results are immediately sent to a cloud server to be analyzed by Optina’s proprietary software that efficiently detects the likely PET amyloid status (Positive or Negative).
Currently, the diagnosis of Alzheimer’s relies on a variety of neurobehavioral tests that are subjective, as well as PET scans that are both expensive and inconvenient.
Driven to impact every segment of the healthcare industry – from researchers to clinicians and pharmaceutical companies – Optina Diagnostics’ vision is to revolutionize the way that Alzheimer’s is diagnosed.
Our research camera is currently sold to academic centers where it is being received with great acclaim.